# IVAX®

IMAX China (1970 HK)
Investor Presentation

Nov 2020



# Disclaimer

This document is not intended to form or provide any basis of any decision in connection with IMAX China Holding, Inc. (the "Company") or any other entity in which it directly or indirectly holds any interest (together with the Company, hereinafter referred to as the "Group"). It does not constitute an offer or an invitation to sell, or an offer or any solicitation of any offer to subscribe for or purchase, any securities in any jurisdiction including but not limited to a jurisdiction in which the making of such offer, invitation, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or would not otherwise be in compliance with the laws and regulations of such jurisdiction. Nothing contained in this document shall form any basis of any decision, contract or commitment whatsoever.

The information in this document has been provided solely for your information. This document does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate the Company and/or any other member of the Group. Certain factual or predictive statements in this document are derived from external sources and have not been independently verified by the Group. No representation or warranty, express or implied, is given, and so far as is permitted by law and except in the case of fraud, no responsibility or liability (in connection with negligence or otherwise) is accepted by any person or entity (which, for the avoidance of doubt, includes but not limited to, any Group member or any of its directors, officers, employees, affiliates, advisers or representatives), with respect to the accuracy, reliability, truthfulness, fairness or completeness of this document or any of its contents or any oral or written communication in connection with any content contained in this document. In particular, but without limitation, no representation or warranty, express or implied, is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this document. None of the Group members or its directors, officers, employees, affiliates, advisers or representatives shall have any liability in respect of the use of, or reliance upon, or any other handling of, any information contained herein by you or any person or entity to whom the information herein is disclosed in any manner. In all cases, each interested party should conduct its/his/her own investigation and analysis of the Group and the information (data or otherwise) contained in this document.

In connection with this document, the Group does not undertake any obligation to provide any additional information or to update this document or any additional information or to correct any inaccuracies which may or may not become apparent. This document does not create any obligation on the Company or any other member of the Group to consider or make any offer.


Ecosystem

Business Model

Investment Thesis


Financials

# Unique Position in the Greater China Entertainment Ecosystem




# Chinese Film Market Sees Room for Growth From Both Demand and Supply Perspective

### Movie admission per capita



### No. of cinema screen per 100,000 population



Source: National Bureau of Statistics, China Film Administration, US Census National Association of Theatre Owners



Investor Presentation

Ecosystem


Business Model

Investment Thesis

Financials


# Our Business Model - Diversifying Monetization

### **IMAX** China business models



# Our Network Effect Drives Higher Recurring Revenue Mix

## Increasing mix of recurring revenue



Note: Recurring revenue refers to box office and network-based revenue

Source: Company data

Ecosystem

Business Model

Investment Thesis

Financials

# Why IMAX China is Well-Positioned as Theatres Reopen?

## Poised for recovery

- ☐ Trusted brand to both audience and exhibitors
- Located in top-performing theatre complexes
- ☐ Pent-up demand for domestic, out-of-home entertainment
- ☐ Strong content pipeline through 2021 with IMAX DNA
- Continue to build new partnerships and expand existing ones
- Robust backlog, majority of which does not require capital commitment

#### Benefit from Structural Tailwinds

- "Blockbusterization" effect
- Local content gravitating towards IMAX genres
  - Drives continued box office market share gain
- Low disruption risks from direct-tostreaming due to unique positioning

### **Financial Strength**


- □ Strong, debt-free balance sheet with net cash balance of US\$75mn as of Sept 30, 2020
- Asset-light business model with limited reopening costs
- No exposure to fixed theatre rental commitment or content production cost
- Consistently return capital to shareholders


Unique premium positioning, strength of our brand, technology and balance sheet gives IMAX China a firm footing

# China's Movie Industry, Particularly IMAX China Network, is Returning to Normalcy Despite Capacity Constraints (1)

#### Attendance as % of normalized 2H 2019 level

#### Gross box office as % of normalized 2H 2019 level





Note (1): Capacity constraint of 30% upon initial reopening on July 20, 2020; 50% effective Aug 14, 2020; and 75%

effective Sept 25, 2020

Note (2): Data from July 20, 2020 to Oct 25, 2020 Source: Top Consulting, including service fee

IMAX China's average attendance and box office since reopening has recovered to second-half 2019 level


# IMAX China Sets Another National Holiday Record as Blockbusterization Continues to Play Out

### 2014-2020 IMAX China National Day Holiday Box Office & Market Share

#### 128 2.2% 2.1% 2.1% 1.9% 1.7% 58 2015 2014 2016 2017 2018 2019 2020 IMAX China box office (in RMB mn) ----- IMAX China market share

Note: 2020 is an 8-day holiday vs. 7-day in previous years Source: Top Consulting, incl. service fee (2017-2020)

#### **IMAX** China box office market share




Note (1): Data from July 20, 2020 to Oct 25, 2020 Source: Top Consulting, including service fee

IMAX China National Holiday Box Office Grew 23% YoY to RMB128mn, marking its largest market share gain in recent years

# Strong Film Slate and Promising Pipeline of Potential Local Language Titles

#### 'The Eight Hundred' (Aug 2020)

- First local title filmed with IMAX Cameras
- Highest-grossing film globally in 2020
- 10<sup>th</sup> highest-grossing title in China film history
- IMAX China box office<sup>1</sup>: RMB123mn
- IMAX opening weekend indexing: 6.5%



#### **'Detective Chinatown 3' (Feb 2021)**


- Filmed with IMAX Cameras
- Presents up to 26% more pictures



#### Note 1: As of Oct 25, 2020

#### 'The Leap' (Sept 2020)

• Industry box office<sup>1</sup>: RMB803mn



#### 'The Rescue' (Feb 2021)

Exhibited in IMAX expanded aspect ratio



#### **'Legend of Deification' (Oct 2020)**

- Best opening weekend for animated film in IMAX China
- Second best opening weekend for local language film in IMAX China
- IMAX China box office1: RMB89mn
- IMAX opening weekend indexing: 7.5%



'Creation of the Gods' (TBD)



#### 'My People My Homeland' (Oct 2020)

- IMAX China box office1: RMB69mn
- IMAX indexing: 2.5%

#### 'The Sacrifice' (Oct 2020)

- IMAX China box office1: RMB21mn
- IMAX indexing: 6.0%



'New Gods: Nezha Reborn' (Feb 2021)



東京/タナル背/教展 week 東州和

'Assassin in Red' (Feb 2021)



= Indicates IMAX DNA



**Investor Presentation** 

# **Blockbuster 2021 Around the Corner**



Bond: No Time to Die



BLACK WIDOW



FAST & FURIOUS 9



GODZILLA VS. KONG





Top Gun: Maverick



SHANG-CHI
and the
Legend of
the Ten
Rings



DUNE



THE ETERNALS



Blockbuster slate extends through 2021

Note: Titles have been confirmed to be released in North America but such release schedule might be postponed due to the COVID-19 pandemic. Release schedule in China to be determined.


# Industry Consolidation an Opportunity, Not a Risk

### Theatre penetration in top 500 complexes in China

### 68% 59% 53% 14% 13% 11% 10% 9% 8% Top 25 Top 50 Top 100 Top 200 Top 500 Industry participant 1 Industry participant 2


Source: TOP Consulting Note: As of 2019

### Gross box office share in top 500 complexes in China



IMAX China is present in 17 out of top 25 highest-grossing complexes


# **Continued Network and Partnership Expansion**



Continued signings and robust backlog provides good visibility to future installations

# **Favorable Structural Tailwind...**

### Total box office of top-10 grossing movies



Contribution of top 10 movies to total industry grossing

Source: TOP Consulting

Top 50 movies generated on average RMB1bn box office in 2019

### Local content gravitating towards IMAX genres



The Wandering Earth (Feb 2019) Highest-grossing local title in IMAX history Third highest-grossing title in China's film history



Ne Zha (July 2019) Second highest-grossing local title in IMAX history Second highest-grossing title in China's film history



The Rescue (CNY 2021) Exhibited in IMAX special aspect ratio



The Eight Hundred (Aug 2020) Filmed with IMAX Cameras Presents up to 26% more pictures



**Detective Chinatown 3 (CNY 2021)** Filmed with IMAX Cameras Presents up to 26% more pictures

Industry tailwind of "Blockbusterization" and "IMAX-able" genres plays into our favor


**Investor Presentation** 

# ...and Our Refined Programming Strategy




#### "The Wandering Earth" - Feb 2019

- Milestone Chinese sci-fi movie with RMB4.66 billion GBO
- First local title to break RMB300 million IMAX GBO in China – third highestgrossing movie in IMAX China history
- Close to 10% IMAX indexing during Chinese New Year



### "Ne Zha" - July 2019

- First local animated film released in IMAX theatre
- Second highest-grossing movie in China film history and fourth highest in IMAX China history
- Highest-grossing animation at all times in China
- 8% IMAX indexing in opening weekend



#### "The Eight Hundred" – Aug 2020

- First local-language title shot entirely with IMAX Cameras
- Tenth highest-grossing movie in China film history
- Highest-grossing film globally in the year 2020
- 6.5% IMAX indexing in opening weekend



#### "Legend of Deification" – Oct 2020

- Best opening weekend for animated film in IMAX China
- Second best opening weekend for local language film in IMAX China
- 7.5% IMAX indexing in opening weekend

Source: Company data

IMAX<sup>®</sup> Investor Presentation

# Drives a consistently High Hit-Rate...

**Top 10 films, 2019 IMAX = 9 out of 10** 





















**Top 10 films, 2018 IMAX = 9 out of 10** 






















**Top 10 films, 2017 IMAX = 8 out of 10** 






















19


Source: Company data

IMAX Investor Presentation

# Rising Box Office Contribution From Local Language Titles

### IMAX China box office distribution (Hollywood vs. Local)

### China box office distribution (Hollywood vs. Local)



Source: Company data, China Film Administration





# ...And Sustainable Market Share Gain


**IMAX China Screen Count Share** 

**IMAX China Box Office Market Share** 

IMAX China Average Box Office Per Title\* (in US\$mn)







Source: Company Data
Note \*: Chinese Mainland only

Ecosystem

Business Model

Investment Thesis

Financials

# Strong Financial Position with Ample Liquidity and Balance Sheet Flexibility

# Strong fundamentals

- ☐ Healthy, debt-free balance sheet
- No exposure to fixed rental commitment or content production cost
- ☐ Flexible, asset-light business model
- ☐ Majority of capex is growth-related

### Cost control actions

- ☐ Three-day or four-day work week for majority of company during theatre closure
- Reduced non-core marketing initiatives, T&E and other nonessential spending

### Financial Strength

- □ US\$75 million in cash as of Sept 30, 2020
- □ Controlled monthly cash burn at US\$1 million under a zero-revenue environment during theatre closure
- ☐ Ample cash runway
- Maintain stable interim dividend payment of US\$7 million

Disciplined cost management over the years builds financial resilience through an extended operational pause



**Investor Presentation** 

# Key Highlights (1H20 vs. 1H19)

Key Financial Highlights (in USD 000, unless otherwise stated)	1H2020	1H2019	YoY change %
Greater China Box Office <sup>1</sup>	7,393	235,959	(96.9%)
Theatre Network (in unit)	714	662	7.9%
Total Revenue	6,662	59,256	(88.8%)
- Network Business	1,120	33,730	(96.7%)
Take-rate <sup>2</sup>	15.1%	14.3%	85 bps
- Theatre Business	5,409	25,381	(78.7%)
Gross Profit	(4,042)	41,047	N.M.
Adjusted EBITDA	(13,424)	38,039	N.M.
Adjusted Net Profit	(15,512)	24,894	N.M.

Note 1: Box office excludes booking fee

Note 2: Take-rate defined as network business revenue divided by IMAX China box office

N.M. = Not meaningful Source: Company data

Temporary closure of our IMAX theatres due to COVID-19 has significantly impacted 1H20 financial results

# Key Highlights (FY19 vs. FY18)


Key Financial Highlights (in USD 000, unless otherwise stated)	FY2019	FY2018	YoY change %
Greater China Box Office <sup>1</sup>	365,807	336,633	8.7%
Mainland China Box Office <sup>1</sup> (in RMB million)	2,367	2,070	14.4%
Theatre Network (in unit)	717	639	12.2%
Total Revenue	124,294	117,520	5.8%
- Network Business	52,918	47,678	11.0%
Take-rate <sup>2</sup>	14.5%	14.2%	30 bps
- Theatre Business	71,033	69,599	2.1%
Gross Profit	76,647	75,251	1.9%
Adjusted EBITDA	68,829	65,016	5.9%
Adjusted Net Profit	44,571	44,283	0.6%
Adjusted Net Margin	35.9%	37.7%	(180) bps

Source: Company data

Record revenue, profit and all time-high box office in FY19


# **Long-term Shareholder Value Creation**

## **Capital returned to shareholders**



Adjusted earnings payout ratio(%)Dividends paidShare buyback

# **Capital expenditure**



As % of total revenueNetwork expansion-related capex

Source: Company data



Investor Presentation 26

